

530 Rec'd PCT

15 JUL 2002

#3

0508-1003

PATENTS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of Confirmation No. 1525
Silvia STINGELE et al.

Serial No. 10/069,576 Box PCT
(PCT/EP00/08223) Attention: DO/EO

Filed February 27, 2002

GENETICALLY ENGINEERED CELL LINES, AND THEIR USES, IN PARTICULAR
FOR NEUROTOXICITY TESTING

RESPONSE TO NOTIFICATION OF MISSING REQUIREMENTS

Assistant Commissioner for Patents

Washington, D.C. 20231

Sir:

In response to the accompanying Notification of Missing Requirements Under 35 U.S.C. 371 mailed May 15, 2002, we enclose herewith the executed declaration which was omitted at the time of filing the application.

The required 37 CFR 1.492(e) surcharge was paid at the time of filing the application.

The requirement for submission of a sequence listing in paper and disk formats is hereby respectfully traversed. None of the sequences disclosed in the present specification is described in terms of a specific articulated nucleotide or amino acid sequence. Consequently, pursuant to 37 C.F.R. §1.821 and 37 C.F.R. §1.825, there is no requirement that a sequence listing be provided.

Attached hereto is a Supplemental Application Data Sheet which provides the corrected addresses of all four inventors.

Respectfully submitted,

YOUNG & THOMPSON

By

Benoît Castel

Benoît Castel
Attorney for Applicants
Registration No. 35,041
745 South 23rd Street
Arlington, VA 22202
Telephone: 703/521-2297

July 15, 2002
Ref. 0508-1003

10 Rec'd 15 JUL 2002

Page 1 of 2



UNITED STATES PATENT AND TRADEMARK OFFICE

 Commissioner for Patents, Box PCT
 United States Patent and Trademark Office
 Washington, D.C. 20231
 www.uspto.gov

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
10/069,576	Silvia Stingle	0508-1003

INTERNATIONAL APPLICATION NO.


PCT/EP00/08223

I.A. FILING DATE	PRIORITY DATE
08/23/2000	08/27/1999

 00466
 YOUNG & THOMPSON
 745 SOUTH 23RD STREET 2ND FLOOR
 ARLINGTON, VA 22202

CONFIRMATION NO. 1525

371 FORMALITIES LETTER



OC000000008097619

Date Mailed: 05/15/2002

NOTIFICATION OF MISSING REQUIREMENTS UNDER 35 U.S.C. 371 IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as an Elected Office (37 CFR 1.495):

- U.S. Basic National Fees
- Priority Document
- Copy of IPE Report
- Copy of references cited in ISR
- Copy of the International Application
- Copy of the International Search Report
- Information Disclosure Statements
- Request for Immediate Examination

The following items **MUST** be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:

- Oath or declaration of the inventors, in compliance with 37 CFR 1.497(a) and (b), identifying the application by the International application number and international filing date.

ALL OF THE ITEMS SET FORTH ABOVE MUST BE SUBMITTED WITHIN TWO (2) MONTH FROM THE DATE OF THIS NOTICE OR BY 22 or 32 MONTHS (where 37 CFR 1.495 applies) FROM THE PRIORITY DATE FOR THE APPLICATION, WHICHEVER IS LATER. FAILURE TO PROPERLY RESPOND WILL RESULT IN ABANDONMENT.

The time period set above may be extended by filing a petition and fee for extension of time under the provisions of 37 CFR 1.136(a).

The following items **MUST** be furnished within the period set forth below:

- The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the

requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason(s):

- This application does not contain a "Sequence Listing" as a separate part of the disclosure on paper copy or compact disc, as required by 37 CFR 1.821(c).
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).
- APPLICANT MUST PROVIDE:
 - An initial or substitute computer readable form (CRF) of the "Sequence Listing."
 - An initial or substitute paper copy or compact disc of the "Sequence Listing," as well as an amendment directing its entry into the specification.

- For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

- This application does not contain a "Sequence Listing" as a separate part of the disclosure on paper copy or compact disc, as required by 37 CFR 1.821(c).
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

*A copy of this notice **MUST** be returned with the response.*

CHRISTINE S WASHINGTON

Telephone: (703) 305-3752

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/069,576	PCT/EP00/08223	0508-1003